-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Srixon Announces Buy 2, Get 1 Free Golf Ball Promotion
-
Ondas and Aston Martin Aramco Formula One Team Launch Multi-Year Partnership Built for "Speed to Decision"
-
Who Does the Best Testosterone Replacement Therapy in Las Vegas?
-
CMP 2026-2027 Nonprofit Leadership Pulse Check
-
Nexteer's HMDD Wins Innovation Awards from PACE Pilot, CES and AutoTech Breakthrough
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
More Than Keyboards: Epomaker Brings Its Gaming World to G-STAR 2026
-
Who Is the Best Spanish-Speaking Private Investigator in Sacramento?
-
Healixa Turns Patents Into Products: FrostPulse(TM) Delivered and Five Eternal Spring(TM) Units Enter Production
-
Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor
-
Cosmos Health Reports Record Nine-Month Revenue of $53.6 Million, Up 18%; Q3 Gross Margin Up 465 Basis Points Sequentially; Total Debt Down 34% and Stockholders' Equity Up 21% Since Year-End
-
Nearly Half of Transformation Initiatives Face a 'Momentum Gap' That Puts Value at Risk, NSP & Company Study Finds
-
CXAI Expands Agentic AI Reach into Mid-Market Through EngineRoom's Simpro Partnership
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Agency Guacamole's 10th B.L.N.D. Event Brought Industry Leaders Together for a Conversation on the Evolution of Diversity and Inclusion in Beauty
-
From Pilot to Production: InHand Networks' Practical Approach to Industrial Edge AI
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
Partnership combines Atlas Mice with Athenova's novel oncology target and expertise in astatine-211-based therapies to accelerate new cancer treatments to the clinic
MOUNTAIN VIEW, CA / ACCESS Newswire / November 18, 2026 / AbTherx, Inc., a privately held biotechnology company accelerating the discovery of next-generation antibody therapeutics, today announced a licensing agreement with Athenova Therapeutics (Athenova), a privately held company based in France developing innovative astatine-211-based targeted alpha therapies against novel oncology targets. Under the agreement, Athenova will use AbTherx's Atlas Full Human Diversity Mice to discover fully human antibodies for its conjugate programs.
Athenova receives full development and commercialization rights to antibodies discovered under the license in exchange for research payments, development milestones, and royalties on net sales. The agreement adds to a growing base of Atlas Platform licensees, ranging from virtual biotechs to top 20 pharmaceutical companies.
"Our focus is simple: build the best antibody discovery technologies and license both the technologies and antibodies discovered using them," said Justin Mika, Chief Executive Officer of AbTherx. "Whether organizations choose to deploy Atlas Mice in-house, collaborate with our team, or leverage our global network of service providers, we offer the flexibility to support antibody discovery in the way that best fits their needs. Athenova is a great example of how we are giving a focused startup access to best-in-class antibody discovery technology through a European service organization, with flexible licensing terms that help it move from target to lead asset in a capital-efficient manner, without unnecessary friction."
"At Athenova, our ambition is to develop next-generation targeted alpha therapies using astatine-211, a promising alpha-emitting radionuclide, for patients with difficult-to-treat cancers. Access to high-quality, fully human antibodies is a critical step in developing these innovative radiopharmaceuticals. AbTherx provides us with world-class antibody discovery technology, access through a European research partner, and startup-friendly business terms that allow us to focus our resources on advancing our therapeutic candidates toward the clinic," said Adrien Reymond, Managing Director of Athenova Therapeutics.
About the Atlas™ Platform
Atlas Mice represent a large step forward in human transgenic mouse technologies for antibody discovery. Atlas Mouse strains available for license include Full Human Diversity (FHD), Common Light Chain (cLC), and Heavy Chain Antibody (HCAb). Every strain was engineered to deliver improved output over legacy transgenic technologies and a clear freedom-to-operate position. Licensees can run Atlas Mouse discovery in-house or through a global network of service organizations across North America, Europe, and Asia.
About AbTherx
AbTherx is a California-based biotechnology company advancing the next generation of antibody therapeutics. By leveraging its proprietary Atlas™ Transgenic Technologies, the company enables the rapid identification of highly diverse, high‑quality, and developable therapeutic candidates for the industry's most challenging drug targets. Built on the deep experience of an industry‑leading scientific team, AbTherx's Atlas Mouse Platform empowers drug developers to reliably deliver innovative medicines to unlock difficult targets with speed and efficiency. For more information, please visit www.abtherx.com.
About Athenova Therapeutics
Founded in 2026 and based in Nantes, France, Athenova Therapeutics is a biotechnology company dedicated to developing next-generation targeted alpha therapies for patients with difficult-to-treat cancers. The company focuses on astatine-211 (²¹¹At), a promising alpha-emitting radionuclide offering significant potential for precision cancer treatment. By combining highly specific targeting molecules with the powerful, short-range radiation emitted by astatine-211, Athenova aims to selectively destroy cancer cells while limiting damage to surrounding healthy tissues. Building on strong scientific expertise and collaborations with leading academic and industrial partners, the company is advancing innovative radiopharmaceutical programs to address significant unmet medical needs in oncology.
AbTherx Media Contact
Stacey Borders
[email protected]
Athenova Therapeutics Media Contact
Elise Berthoud
[email protected]
SOURCE: AbTherx, Inc
View the original press release on ACCESS Newswire
T.Perez--AT